**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 2521**

**Columns: ORIGINAL ARTICLE**

# Clinically detected gastro­entero­pancreatic neuroendocrine tumors are on the rise: Epidemiological changes in Germany

Scherübl H *et al*. Clinically detected GEP-NETs are on the rise

Hans Scherübl, Brigitte Streller, Roland Stabenow, Hermann Herbst, Michael Höpfner, Christoph Schwertner, Joachim Steinberg, Jan Eick , Wanda Ring, Krishna Tiwari, Sören M Zappe

**Hans Scherübl, Christoph Schwertner, Joachim Steinberg, Jan Eick, Wanda Ring, Krishna Tiwari,** Klinik für Gastroenterologie, GI Onkologie und Infektiologie, Vivantes Klinikum Am Urban, 10967 Berlin, Germany

**Brigitte Streller,** **Roland Stabenow,** Gemeinsames Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen-Anhalt und der Freistaaten Sachsen und Thüringen (GKR), Berlin, Germany

**Hermann Herbst,** Institut für Pathologie, Vivantes Netzwerk für Gesundheit GmbH, 10967 Berlin, Germany

**Michael Höpfner,** Institut für Physiologie,Charité-Universitätsmedizin, 13353 Berlin, Germany

**Sören M Zappe,** Charité-Universitätsmedizin Berlin, HNO-Klinik, Campus Virchow Klinikum, 13353 Berlin, Germany

**Author contributions:** Scherübl H analyzed data and wrote the paper; Streller B, Stabenow R performed research; Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K analyzed data; Zappa S performed research and wrote the paper.

**Correspondence to: Dr. Hans Scherübl, Professor,** Klinik für Gastroenterologie, GI Onkologie und Infektiologie, Vivantes Klinikum Am Urban, Akademisches Lehrkrankenhaus der Charité Dieffenbachstrasse 1, 10967 Berlin, Germany.

hans.scheruebl@vivantes.de

**Telephone:** +49-301-30225201  **Fax:** +49-301-30225205

**Received:** February 25, 2013 **Revised:** July 17, 2013

**Accepted:** September 16, 2013

**Published online:**

**Abstract**

**AIM:** To study the epidemiologic changes of gastroenteropancreatic neuroendocrine tumors (GEP-NET) in Germany, we analyzed two time periods 1976-1988 and 1998-2006.

**METHODS:** We evaluated epidemiological data of GEP-NET from the former East German National Cancer Registry (DDR Krebsregister, 1976-1988) and its successor, the Joint Cancer Registry (GKR, 1998-2006), which was founded after German reunification. Due to a particularly substantial database the epidemiological data from the federal states of Mecklenburg-Western Pomerania, Saxony, Brandenburg and Thuringia, covering a population of more than 10.8 million people, were analyzed. Survival probabilities were calculated using life table analysis. In addition, GEP-NET patients were evaluated for one or more second (non-GEP-NET) primary malignancies.

**RESULTS:** A total of 2821 GEP neuroendocrine neoplasms were identified in the two registries. The overall incidence increased significantly between 1976 and 2006 from 0.31 (per 100000 inhabitants per year) to 2.27 for men and from 0.57 to 2.38 for women. In the later period studied (2004-2006), the small intestine was the most common site. Neuroendocrine (NE) neoplasms of the small intestine showed the largest absolute increase in incidence, while rectal NE neoplasms exhibited the greatest relative increase. Only the incidence of appendiceal NET in women showed little change between 1976 and 2006. Overall survival of patients varied for sex, tumor site and the two periods studied but improved significantly over time. Interestingly, about 20% of the GEP-NET patients developed one or more second malignancies. Their most common location was the gastrointestinal tract. GEP-NET patients without second malignancies fared better than those with one or more of them.

**CONCLUSION:** The number of detected GEP-NET increased about 5-fold in Germany between 1976 and 2006. At the same time, their anatomic distribution changed, and the survival of GEP-NET patients improved significantly. Second malignancies are common and influence the overall survival of GEP-NET patients. Thus, GEP-NET warrant our attention as well as intensive research on their tumorigenesis.

© 2013 Baishideng. All rights reserved.

**Key words:** Neuroendocrine; Tumor; Epidemiology; Gastrinoma; Insulinoma; Endoscopy; German history; Reunification; Second malignancy

**Core tip:** Modern endoscopic and radiological tumor imaging have been implicated in the rise of the incidence of detected neuroendocrine tumors (NET) in Western countries. The particularities of German history, which resulted in two German states with two different health care systems from 1949-1989, allowed to study the epidemiological changes of NET in Germany on the background of two health care systems in 1949-1989. The number of detected gastroenteropancreatic-NET increased about 5-fold between 1976 and 2006. Most likely, the general availability of endoscopy after German reunification contributed to the major rise in frequency of detected rectal, gastric and duodenal NET in the new federal states of reunified Germany.

Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K, Zappe SM. Clinically detected gastro­entero­pancreatic neuroendocrine tumors are on the rise: Epidemiological changes in Germany. *World J Gastroenterol* 2013;

**Available from:** URL: http://www.wjgnet.com/esps/

**DOI:** http://dx.doi.org/10.3748/wjg.v19.i0.0000

**INTRODUCTION**

Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are infrequent, constituting only 1%–2% of all neoplasms. Most commonly they present as indolent, slow-growing tumors[1-4]. Their anatomic distribution reflects that of the neuroendocrine cells from which they derive: up to 65% in the gastrointestinal tract, about 25% in the bronchopulmonary system, and the remaining 10% at other sites[1,5].

In Western countries, pancreatic neuroendocrine tumors are diagnosed in 0.5-1 per 100000 inhabitants and represent 1%–2% of all clinically manifest pancreatic neoplasms[6-8]. GEP-NET occur in approximately 2.0–2.5 per 100000, carcinoid syndrome being most frequently associated with NET of the jejunum and ileum[9-13].

Previous and current WHO classifications distinguish between well-differentiated and poorly differentiated neoplasms. All well-differentiated neoplasms, whether benign or metastatic, are now called NE) and are graded as G1 (Ki-67 ≤ 2%) or G2 (Ki-67: 3%-20%). The poorly differentiated neoplasms are called neuroendocrine carcinomas and are graded as G3 (Ki-67 > 20%). The term “carcinoid” is now synonymous with G1 well-differentiated neuroendocrine tumor.

Population-based data from the Third National Cancer Survey and the US Surveillance Epidemiology and End Results (SEER) Program, covering 10%–14% of the US population, show a steady increase in the incidence of NET throughout the 35-year period between 1969 and 2004[14-16]. The overall incidence of GEP-NET increased two- to three-fold during this period, and there were significant changes in the anatomic distribution. Thus, the proportion of GEP-NET located in the appendix decreased from 43% to 4% with corresponding increases in the stomach (from 2% to 9%), small intestine (from 31% to 42%), and rectum (from 15% to 27%)[18]. The observed changes may in part reflect the increased number of asymptomatic GEP-NET incidentally identified thanks to increased availability of modern endoscopic and radiological imaging[8,17].

There have been few studies on GEP-NET epidemiology in Germany[18], and no comprehensive and comparative epidemiological studies have as yet been published on GEP-NET at various locations.

Therefore we evaluated epidemiological data from the former East German National Cancer Registry (DDR Krebsregister) for 1976-1988 and from its successor, the Joint Cancer Registry (GKR) for 1998-2006. After German reunification, the East German registry was renamed and thus became the Joint Cancer Registry (GKR) of the new federal states of Germany and Berlin. After an interruption of several years, it continued to collect epidemiological data. Thanks to a particularly substantial database we analyzed epidemiological data from the federal states of Mecklenburg-Western Pomerania, Saxony, Brandenburg and Thuringia, covering a population of over 10.8 million people.

**MATERIALS AND METHODS**

The official population statistics for Germany as reported by the German government were used to estimate the incidence rate of GEP-NET. Absolute numbers were used to estimate the crude incidence rate both in former East Germany and - after German reunification - in the new federal states, including Berlin. A particularly substantial database enabled us to analyze epidemiological data from the federal states of Mecklenburg-Western Pomerania, Saxony, Brandenburg and Thuringia, covering a population of more than 10.8 million people. Since other federal states, including Berlin, had a less extensive database, their data were not used in the analysis presented here.

The study included all persons (living in Mecklenburg-Western Pomerania, Saxony, Brandenburg or Thuringia) diagnosed with GEP-NET between 1976 and 1988 or between 1998 and 2006. Mortality data from 1976 to 1990 and from 1998 to 2009 were used. We included all patients with NE tumors at the following tumor sites according to ICD10: C15-C25, D37.1-D37.5 (esophagus, stomach, small intestine, large intestine, appendix, rectosigmoid, rectum, anus and pancreas), C26.0, C26.8-9, D37.7, D37.9 (unspecified location in the digestive tract) and an NE morphology code according to ICD-O-3: 8150-8153, 8155-8157, 8240-8246, 8249 or 8574.

Annual incidence rates were calculated for the periods 1976-1988 and 1998-2006. Incidence rates are presented for each tumor site, sex and age group. Trends in incidence are presented as overall change throughout the two periods and between two representative 2-year periods, *i.e.,* 1976-1978 and 2004-2006. The absolute number of GEP-NET reported per 100000 inhabitants per year is referred to as the “crude incidence rate”.

Age-adjusted incidence rates were calculated using the World Standard Population published in 1966[5] and the 1987 German standard population.

Survival probabilities were calculated using life table analysis. Since data were available only on the time but not the cause of death, only the overall survival of the registered GEP-NET patients could be determined. Tumor-specific survival could not be analyzed. The Wilcoxon-Gehan test was used to determine significance when comparing the survival rates.

In addition, all GEP-NET patients were evaluated for one or more second primary malignancies. Second (non-GEP-NET) neoplasms were analyzed for location of the second primary.

**RESULTS**

***Frequency***

From 1976 to 1988 and from 1998 to 2006, a total of 2821 cases of GEP-NET were registered in Mecklenburg-Western Pomerania, Saxony, Brandenburg and Thuringia - 1001 cases from 1976 to 1988 and 1820 cases from 1998 to 2006. The total patient population comprised 1291 men (45.8%) and 1530 women (54.2%).

In 2006, a total of 10,837,539 persons lived in Mecklenburg-Western Pomerania, Saxony, Brandenburg and Thuringia - 5329539 men (49.2%) and 5508000 women (50.8%).

***Incidence rates***

The crude incidence rate of GEP-NET (per year and 100000 population) rose from 0.45 in 1976 to 2.53 in 2006, which corresponds to a 462% increase. The incidence rate increased by 342% when age-adjusted to the 1966 world population and by 270% when adjusted to the 1987 population of Germany (for details, Figure 1).

The crude incidence rate increased more prominently in men (from 0.31 in 1976 to 2.7 in 2006) than in women (from 0.57 in 1976 to 2.38 in 2006).

***Tumor site***

The age-adjusted (population of Germany in 1987) incidence is given in Table 1 for the periods 1976-1988 and 1998-2006. Both age-adjusted and crude incidence rates increased at all tumor sites. When comparing representative time intervals such as 1976-1978 and 2004-2006, the largest increment in absolute numbers was found for the small intestine; the absolute increase in crude incidence was 0.56 in men and 0.48 in women. Focusing on relative changes revealed the largest increase for rectal NE neoplasms; the crude incidence rose by about 6000% in men and by more than 2700% in women. In contrast, hardly any change was observed for appendiceal NE neoplasms in the female population between 1976 and 2006 (Figures 2 and 3).

***Survival***

Overall survival increased significantly between the time periods 1976-1988 and 1998-2006 (*P* < 0.001). The 1-, 5- and 10-year overall survival rates were 59%, 50% and 47% for the earlier period and 79%, 63% and 50% for the later period (Figure 4).

 Overall survival differed significantly (*P* < 0.001) between men and women. In the earlier period (1976-1988), 51% of men and 64% of women were alive after 1 year; 43% of men and 55% of women stayed alive after 5 years, and 41% of men and 51% of women were alive after 10 years. In the later period (1998-2006), 1-year survival was 75% for men and 83% for women; 5-year survival had increased to 57% for men and 68% for women, and 10-year survival was 42% for men and 58% for women. Overall survival differed not only for sex but also for the primary tumor site. Table 2 shows significant differences in survival for various anatomic locations of the primary as well as for the two time periods (1976-1988 and 1998-2006).

***Second primary neoplasms***

Of the 2821 NE tumor patients diagnosed between 1976-1988 and 1998-2006, 472 developed 533 second malignancies (Figure 5). The 533 second malignancies were diagnosed as pre-existing, synchronous or metachronous malignancies during the same time intervals as the GEP-NET (1976-1988 or 1998-2006); 16.7% of the GEP-NET patients suffered from second neoplasms.

GEP-NET patients without second malignancies fared better than those with one or more of them. An analysis of all 2821 GEP-NET patients showed significantly better 5- and 10-year overall survival for those without than for those with one or more second malignancies (5-year survival of 60% *vs* 53%; 10-year survival of 52% *vs* 42%; *P* < 0.05).

 The main locations of second malignancies were the digestive tract (28%), the female genital organs (12%), the skin (12%), the breasts (7%) and the male genital organs (7%).

**DISCUSSION**

Analysis of the former East German National Cancer Registry (DDR Krebsregister) for the period 1976-1988 and its successor, the Joint Cancer Registry (GKR), for the period 1998-2006 revealed major increases in the incidence of detected GEP-NET in Germany. Our findings are in line with a recent report from the United States American SEER registry[17]. Recent epidemiological data from England and Norway also showed increases[3,8]. The current incidence of GEP-NET in Germany compares well with the incidence rates found in the United States and Australia as well as in several other European countries, *i.e.,* 1.33 to 3.8 per 100,000[3,15,37]. Despite these similarities, there are a number of important differences.

The nomenclature and classifications of NE neoplasms have not been uniform in the last 35 years[19]. Thus the low incidence rates from 1976-1988 may in part reflect differences between the classification and nomenclature used by East German pathologists (of the DDR Krebsregister) and those applied elsewhere. On the other hand, recent improvements in the general awareness and immunohistological diagnosis of NE neoplasms may have contributed to increased incidences in the last 20 years.

Moreover, colorectal cancer screening and the general availability of high-resolution endoscopy and radiological imaging may well have facilitated the detection of early asymptomatic GEP-NET. The hypothesis is supported by studies demonstrating that the incidence and anatomic distribution differ significantly between tumors detected post mortem and those diagnosed clinically[7,11]. These studies suggest that most small (≤ 1 cm) GEP-NET remain asymptomatic and were generally not diagnosed in the era before the widespread availability of high-resolution endoscopy and CT imaging.

The question arises whether the increased detection of early (asymptomatic) NET disease has contributed to recent epidemiological trends. In recent years, localized NET constitute by far the largest subgroup in the SEER registry and are largely responsible for the increased incidence of GEP-NET[16]. Consistent with this notion, Japanese, South Korean and Polish endoscopy screening programs detected rectal NET in 50-70 of 100000 persons screened[19-21]. The vast majority of rectal NE neoplasms detected by screening are 1 cm or smaller in diameter. Comparison with historical registries shows that screening is associated with a shift to smaller-sized rectal NET[17,22]. A national program of endoscopic colorectal cancer screening was introduced in Germany in October 2002. Screening colonoscopy is now offered free of charge to any person aged 55 years or older. Both colonoscopy and esophagogastroduodenoscopy are now readily available in Germany. In former East Germany (up to 1989), on the other hand, gastrointestinal endoscopy was available only at 3-4 centers.

The now widespread availability of endoscopy and radiological imaging may well have contributed to the observed increases in gastroduodenal, rectal and pancreatic NET[23-26]. On the other hand, the incidence of appendiceal NET remained quite stable in the Eastern parts of Germany from 1976 to 2006. Even today, they are generally diagnosed postoperatively in patients who undergo appendectomy for suspected appendicitis. Endoscopy and radiological imaging probably do not have much impact on their early detection (≤ 1 cm). Instead, they are found incidentally in one out of 200-300 appendectomy specimens. Appendectomies are among the most common surgical procedures performed in Germany. They account for 135000 procedures per year. This contributes to the frequent detection of early appendiceal NET[28].

In line with recent reports from England[27] and Austria[28], we observed a large increase in the incidence of gastric NET. In the current analysis, however, the nature of the epidemiological data does not enable an examination of underlying causes. Noteworthy is the fact that the incidence rates of both gastric and rectal carcinoids are most likely underestimated in the former East German National Cancer Registry (DDR Krebsregister) as well as in its successor registry, the Joint Cancer Registry (GKR) of the new federal states, including Berlin. This is due to the fact that only malignant NE neoplasms had to be reported to either registry. Thus, well-differentiated small (< 1-2 cm) carcinoids of the stomach or rectum were probably not consistently documented in the past. Recent prospective data from Austria identify the stomach and colorectum as the most common sites of GEP-NET[28]. The Austrian observation has been confirmed by a retrospective study including 150 consecutive GEP-NET patients diagnosed at the Vivantes Hospitals in Berlin between 2005 and 2009. The stomach was the most frequent site of GEP-NET in the Vivantes Hospitals, closely followed by the small intestine and colorectum (data not shown).

Overall survival of GEP-NET patients has improved significantly in Germany during the last 35 years. This applies to both sexes and all examined anatomic sites except the appendix. In the latter location, overall survival decreased in women and remained unchanged in men. But even in the period 1998-2006, the 5- and 10-year survival reached 86% and 81%. The significant improvement in overall survival of GEP-NET patients can probably be attributed to earlier diagnosis, the greater effectiveness of modern multimodal treatment strategies, and the general increase in life expectancy.

 Only a few studies have reported on the frequency of one or more second malignancies in GEP-NET patients. Second primaries were found in 16.7% of our GEP-NET patients. This is consistent with data from Florida (23.6%), a meta-analysis from 13 studies including more than 5000 GEP-NET patients (17%), and the SEER registry (22.4%)[15,29,30]. At 28%, the incidence of these second primaries was highest in the gastrointestinal tract and much lower at 12% in both the female genital tract and the skin. These data on second malignancies are consistent with the observations reported in the studies mentioned above.

GEP-NET patients appear to have an increased risk of second malignancies, although there is an ongoing debate. In their review, Habal *et al*[29] summarize several theories regarding the influence of NET on the emergence and growth of second malignancies. They estimated that the risk of developing a second tumor is twice as high for patients with GEP-NET than for those with other neoplasms[29]. Several studies have examined amines, peptides, growth hormones and other compounds secreted by NET for their relation to the formation and growth of neoplasms in the breast or gastrointestinal tract[31-33].

Due to the high prevalence of second neoplasms, screening for other malignancies seems advisable in GEP-NET patients. Remarkably, Zar *et al*[34] observed that many GEP-NET patients died of their second malignancies but not of their GEP-NET. Consistent with the data of Zar *et al*[34], our GEP-NET patients with one or more second malignancies did not fare as well as those without them.

We conclude that both the frequency of detected GEP-NET and the overall survival of GEP-NET patients have increased significantly in Germany between 1976 and 2006. These epidemiological changes warrant our attention. Future research efforts will focus on the carcinogenesis of GEP-NET.

**ACKNOWLEDGEMENTS**

This publication is part of the medical thesis (“Doktorarbeit”) submitted by Zappe SM to the Charité-Universitätsmedizin Berlin.

**COMMENTS**

***Background***

Neuroendocrine tumors belong to the three malignancies that increase most in frequency in Western countries.

***Research frontiers***

The genetic footprints of neuroendocrine neoplasias are about to be unravelled.

***Innovations and breakthroughs***

The frequency of second malignancies in neuroendocrine tumors (NET) patients is highlighted in this paper. The power of screening endoscopy in detecting small neuroendocrine tumors (*e.g.,* of the rectum) is evidenced by its availability in former East Germany after German reunification in 1989.

***Applications***

The general availability of modern endoscopy enables the (early) detection of small neuroendocrine tumors of the stomach, duodenum and rectum. Detection of small asymptomatic neuroendocrine tumors appears to have contributed to their epidemiological rise.

***Peer review***

The authors describe an increase of gastroenteropancreatic-NET (GEP-NET) for the time period 1977-1988 to 1998-2006 by five-fold. However, they quite clearly demonstrated in the discussion section that this increase is mainly due to different reasons: Nomenclature has been changed; improvement of general awareness and immunological diagnoses; availability of the German National Programme of Colorectal Cancer Screening since October 2002; better imaging diagnoses. An important finding of the project is that almost 17 per cent of GEP-NEN patients showed second primary malignancies and therefore screening for other malignancies in those patients should be important for the future.

**REFERENCES**

1 **Berge T**, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. *Acta Pathol Microbiol Scand A* 1976; **84**: 322-330 [PMID: 961424 DOI: 10.1111/j.1699-0463.1976.tb00122.x]

2 **Oberg K**, Eriksson B. Endocrine tumours of the pancreas. *Best Pract Res Clin Gastroenterol* 2005; **19**: 753-781 [PMID: 16253899 DOI: 10.1016/j.bpg.2005.06.002]

3 **Scherübl H**, Jensen RT, Cadiot G, Stölzel U, Klöppel G. Management of early gastrointestinal neuroendocrine neoplasms. *World J Gastrointest Endosc* 2011; **3**: 133-139 [PMID: 21860682 DOI: 10.4253/wjge.v3.i7.133]

4 **Soga J**. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. *Cancer* 2005; **103**: 1587-1595 [PMID: 15742328 DOI: 10.1002/cncr.20939]

5 **Doll R**, Payne PM, Waterhouse JAH. Cancer incidence in five countries. International Union Against Cancer, Springer-Verlag. Berlin, 1966

6 **Eriksson B**, Oberg K. Neuroendocrine tumours of the pancreas. *Br J Surg* 2000; **87**: 129-131 [PMID: 10671915 DOI: 10.1046/j.1365-2168.2000.01277.x]

7 **Lam KY**, Lo CY. Pancreatic endocrine tumour: a 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. *Eur J Surg Oncol* 1997; **23**: 36-42 [PMID: 9066745 DOI: 10.1016/S0748-7983(97)80140-0]

8 **Modlin IM**, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. *Lancet Oncol* 2008; **9**: 61-72 [PMID: 18177818 DOI: 10.1016/S1470-2045(07)70410-2]

9 **Quaedvlieg PF**, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. *Ann Oncol* 2001; **12**: 1295-1300 [PMID: 11697843 DOI: 10.1016/S0016-5085(08)81267-X]

10 **Oberg K**, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH, Välimäki M. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. *Acta Oncol* 2004; **43**: 617-625 [PMID: 15545182 DOI: 10.1080/02841860410018575]

11 **Oberg K**, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH, Välimäki M. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. *Acta Oncol* 2004; **43**: 626-636 [PMID: 15545183 DOI: 10.1080/02841860410018584]

12 **Plöckinger U**, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC, Nilsson O, Delle Fave G, Ruszniewski P, Ahlman H, Wiedenmann B. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). *Neuroendocrinology* 2004; **80**: 394-424 [PMID: 15838182]

13 **Tomassetti P**, Campana D, Piscitelli L, Casadei R, Nori F, Brocchi E, Santini D, Pezzilli R, Corinaldesi R. Endocrine tumors of the ileum: factors correlated with survival. *Neuroendocrinology* 2006; **83**: 380-386 [PMID: 17016032 DOI: 10.1159/000096053]

14 **Hauso O**, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM. Neuroendocrine tumor epidemiology: contrasting Norway and North America. *Cancer* 2008; **113**: 2655-2664 [PMID: 18853416 DOI: 10.1002/cncr.23883]

15 **Modlin IM**, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. *Cancer* 2003; **97**: 934-959 [PMID: 12569593 DOI: 10.1002/cncr.11105]

16 **Yao JC**, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol* 2008; **26**: 3063-3072 [PMID: 18565894 DOI: 10.1200/JCO.2007.15.4377]

17 **Scherübl H**. Rectal carcinoids are on the rise: early detection by screening endoscopy. *Endoscopy* 2009; **41**: 162-165 [PMID: 19214898 DOI: 10.1055/s-0028-1119456]

18 **Stang A**, Stegmaier C, Eisinger B, Stabenow R, Metz KA, Jöckel KH. Descriptive epidemiology of small intestinal malignancies: the German Cancer Registry experience. *Br J Cancer* 1999; **80**: 1440-1444 [PMID: 10424748 DOI: 10.1038/sj.bjc.6690541]

19 **Kaminski M**, Polkowski M, Regula J. Prevalence and endoscopic features of rectal neuroendocrine tumors (carcinoids) among 50148 participants of the Polish colorectal-cancer screening programe. *Gut* 2007; **56**: A310

20 **Matsui K**, Iwase T, Kitagawa M. Small, polypoid-appearing carcinoid tumors of the rectum: clinicopathologic study of 16 cases and effectiveness of endoscopic treatment. *Am J Gastroenterol* 1993; **88**: 1949-1953 [PMID: 8237948]

21 **Shim KN**, Yang SK, Myung SJ, Chang HS, Jung SA, Choe JW, Lee YJ, Byeon JS, Lee JH, Jung HY, Hong WS, Kim JH, Min YI, Kim JC, Kim JS. Atypical endoscopic features of rectal carcinoids. *Endoscopy* 2004; **36**: 313-316 [PMID: 15057680 DOI: 10.1055/s-2004-814202]

22 **Klöppel G**, Scherübl H. [Neuroendocrine neoplasms of the appendix and colorectum]. *Pathologe* 2011; **32**: 314-320 [PMID: 21655999 DOI: 10.1007/s00292-011-1438-y]

23 **Ito T**, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K, Doi R, Shimatsu A, Nishida T, Komoto I, Hirata Y, Nakamura K, Igarashi H, Jensen RT, Wiedenmann B, Imamura M. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. *J Gastroenterol* 2010; **45**: 234-243 [PMID: 20058030 DOI: 10.1007/s00535-009-0194-8]

24 **Kvols LK**, Brendtro KL. The North American Neuroendocrine Tumor Society (NANETS) guidelines: mission, goals, and process. *Pancreas* 2010; **39**: 705-706 [PMID: 20664469 DOI: 10.1097/MPA.0b013e3181eb7451]

25 **Scherübl H**, Cadiot G, Jensen RT, Rösch T, Stölzel U, Klöppel G. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? *Endoscopy* 2010; **42**: 664-671 [PMID: 20669078 DOI: 10.1055/s-0030-1255564]

26 **Scherübl H**, Jensen RT, Cadiot G, Stölzel U, Klöppel G. Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management. *World J Gastrointest Endosc* 2010; **2**: 325-334 [PMID: 21160582 DOI: 10.4253/wjge.v2.i10.325]

27 **Ellis L**, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. *Am J Gastroenterol* 2010; **105**: 2563-2569 [PMID: 20823835 DOI: 10.1038/ajg.2010.341]

28 **Niederle MB**, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. *Endocr Relat Cancer* 2010; **17**: 909-918 [PMID: 20702725 DOI: 10.1677/ERC-10-0152]

29 **Habal N**, Sims C, Bilchik AJ. Gastrointestinal carcinoid tumors and second primary malignancies. *J Surg Oncol* 2000; **75**: 310-316 [PMID: 11135275 DOI: 10.1002/1096-9098(200012)75: 4<306]

30 **Perez EA**, Koniaris LG, Snell SE, Gutierrez JC, Sumner WE, Lee DJ, Hodgson NC, Livingstone AS, Franceschi D. 7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly. *World J Surg* 2007; **31**: 1022-1030 [PMID: 17429568 DOI: 10.1007/s00268-005-0774-6]

31 **Gerstle JT**, Kauffman GL, Koltun WA. The incidence, management, and outcome of patients with gastrointestinal carcinoids and second primary malignancies. *J Am Coll Surg* 1995; **180**: 427-432 [PMID: 7719546]

32 **Rehfeld JF**. The new biology of gastrointestinal hormones. *Physiol Rev* 1998; **78**: 1087-1108 [PMID: 9790570]

33 **Zucker KA**, Longo WE, Modlin IM, Bilchik AJ, Adrian TE. Malignant diathesis from jejunal-ileal carcinoids. *Am J Gastroenterol* 1989; **84**: 182-186 [PMID: 2644819]

34 **Zar N**, Garmo H, Holmberg L, Hellman P. Risk of second primary malignancies and causes of death in patients with adenocarcinoma and carcinoid of the small intestine. *Eur J Cancer* 2008; **44**: 718-725 [PMID: 18207733 DOI: 10.1016/j.ejca.2007.12.003]

**P-Reviewers** Bloomston M, Filsch UR **S-Editor** Gou SX  **L-Editor E-Editor**

**Figure 1 The incidence of gastro­entero­pancreatic neuroendocrine tumors is shown over time (1976-1988 and 1998-2006).** It is presented either as crude incidence or as the number of tumors (per 100000) age-adjusted to the 1966 world standard population (World standard) or to the 1987 German standard population (German standard). The data shown originate from the former East German National Cancer Registry (DDR Krebsregister) for 1976-1988 or from its successor, the Joint Cancer Registry (GKR), for 1998-2006.

**Relative change of incidenceRelative change of incidence**

5555

1313

370370

252252

353353

494494

00

100100

200200

300300

400400

500500

600600

MenMen

WomenWomen

MenMen

WomenWomen

MenMen

WomenWomen

AppendixAppendix

Small intestineSmall intestine

ColonColon

**Relative change of incidence (%)Relative change of incidence (%)**

A



B

**Figure 2 Relative changes in the incidence of gastro­entero­pancreatic neuroendocrine tumor are depicted according to tumor site and sex.** A: Changes were calculated for the reference periods 1976-1978 and 2004-2006; the intervals 1979-1981 and 2004-2006 were chosen for the stomach, since no gastric NE neoplasms were registered in women before 1979; B: Changes in incidence are presented as relative increments age-adjusted to the 1987 German standard population. The data shown originate from the former East German National Cancer Registry (DDR Krebsregister) for the years 1976-1978 or from its successor, the Joint Cancer Registry (GKR), for the time period 2004-2006.



A



B

**Figure 3 Absolute changes in the incidence of gastro­entero­pancreatic neuroendocrine tumor are shown according to tumor site and sex.** A: Changes were calculated for the reference periods 1976-1978 and 2004-2006; the periods 1979-1981 and 2004-2006 were chosen for the stomach, since no registered gastric NE neoplasms were registered in women before 1979; B: Changes in incidence are presented as absolute increments age-adjusted to the 1987 German standard population. The data shown originate from the former East German National Cancer Registry (DDR Krebsregister) for the years 1976-1978 or from its successor, the Joint Cancer Registry (GKR), for the time period 2004-2006.

**Figure 4 Overall survival of patients with gastro­entero­pancreatic neuroendocrine tumor.** Two periods of time are compared (1976-1988 and 1998-2006).GEP-NET: Gastro­entero­pancreatic neuroendocrine tumor.



A



B

**Figure 5 Second malignancies occurred in 472 of 2821 patients with gastro­entero­pancreatic neuroendocrine tumor.** A: The absolute number; B: The percentage of patients with one or more second (non-gastro­entero­pancreatic neuroendocrine tumor, non-GEP-NET) neoplasms. 0 = No second neoplasm.

**Table 1 Incidence of gastroenteropancreatic neuroendocrine tumors according to anatomic site, sex, and the time periods 1976-1988 and 1998-2006**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Period** | **Stomach (M/F)1** | **Small intestine (M/F)1** | **Pancreas (M/F)1** | **Appendix (M/F)1** | **Colon****(M/F)1** | **Rectum****(M/F)1** |
| 1976-1978 | 0.02/0 | 0.11/0.15 | 0.03/0.08 | 0.20/0.35 | 0.04/0.05 | 0.01/0.01 |
| 1979-1981 | 0.04/0.03 | 0.10/0.11 | 0.07/0.014 | 0,15/0.34 | 0.04/0.07 | 0.01/0.03 |
| 1982-1984 | 0.04/0.04 | 0.16/0.12 | 0.11/0.08 | 0.15/0.35 | 0.04/0.07 | 0.03/0.02 |
| 1985-1988 | 0.05/0.04 | 0.20/0.18 | 0.10/0.10 | 0.24/0.35 | 0.08/0.15 | 0.03/0.07 |
| 1989-1997 |  |  |  |  |  |  |
| 1998-2000 | 0.16/0.12 | 0.39/0.31 | 0.22/0.18 | 0.13/0.28 | 0.19/0.19 | 0.09/0.10 |
| 2001-2003 | 0.18/0.18 | 0.44/0.40 | 0.25/0.25 | 0.23/0.46 | 0.22/0.23 | 0.16/0.15 |
| 2004-2006 | 0.27/0.23 | 0.51/0.52 | 0.25/0.25 | 0.31/0.39 | 0.20/0.28 | 0.26/0.24 |

**1**Male/female (M/F) patients. Incidence rates were age-adjusted to the German standard population of 1987. The data shown originate from the former East German National Cancer Registry (DDR Krebsregister) for the years 1976-1988 or from its successor, the Joint Cancer Registry (GKR) for the time period 1998-2006. No valid data are available for the period between 1989 and 1997.

Table 2 1-, 5- and 10-year overall survival of patients with gastroenteropancreatic neuroendocrine tumors

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Overall-survival/period** | **Stomach** | **Small intestine** | **Pancreas** | **Appendix** | **Colon** | **Rectum** |
| 1-yr/1976-1988 | 22% | 30% | 26% | 95% | 35% | 50% |
| 5-yr/1976-1988 | 11% | 18% | 11% | 92% | 16% | 37% |
| 10-yr/1976-1988 | 5% | 10% | 8% | 90% | 13% | 37% |
| 1-yr/1998-2006 | 71% | 85% | 74% | 95% | 68% | 74% |
| 5-yr/1998-2006 | 53% | 68% | 52% | 86% | 48% | 65% |
| 10-yr/1998-2006 | 43% | 53% | 35% | 81% | 34% | 50% |

Data are given for different primary tumor sites and two periods of time (1976-1988 and 1998-2006).